Ingersoll Rand is a mission-critical industrial compounder executing a disciplined M&A flywheel (16 deals in 2025, $525M deployed at ~9x pre-synergy multiples) layered on top of a sticky installed-base model where aftermarket revenue (~37% of sales) grows faster than equipment sales. The company's 'region-for-region' manufacturing strategy and diversified end-market exposure provide resilience against tariff and macro headwinds, while the Precision & Science Technologies segment's life sciences exposure (mid-teens organic order growth) offers a secular growth vector.
| Scenario | Prob. | Target | Driver |
|---|---|---|---|
| Bull | 25% | $110.00 | Organic revenue growth accelerates to 3-5% as industrial cycle recovers in H2 2026 |
| Base | 50% | $91.00 | Revenue grows 2.5-4.5% as guided, with organic growth flat to low single digits |
| Bear | 25% | $66.00 | Industrial recession drives negative organic growth — end-market demand deteriorates beyond tariff impacts |
Initial coverage — Phase A deep research
Positioning skews toward near-term upside